A degree from Boston College graduating in 1984

Murphy is a 1999 graduate of the General Manager Program at Harvard BusinessSchool and holds a B.A degree from Boston College, graduating in 1984. In 1999, he receivedBoston Colleges "Rising Star Award" in recognition of his distinguished serviceto the university. About Putnam InvestmentsFounded in 1937, Putnam Investments is a leading global money management firmwith over 70 years of investment experience. As of December 31, 2008, Putnammanaged $106 billion in assets.

Putnam has offices in Boston, London, Tokyo,Singapore and Sydney. The prospectus includes investmentobjectives, risks, fees, expenses, and other information that you should readand consider carefully before investing.Putnam mutual funds are distributed by Putnam Retail Management. Putnam InvestmentsLaura McNamara, 617-760-1108orPutnam InvestmentsSinead Martin, 617-760-8515orThe Hubbell Group, Inc.Constance Hubbell, 781-878-8882 (office)617-529-3700 (cell)Copyright Business Wire 2009. MONMOUTH JUNCTION, NJ, Feb 03 (MARKET WIRE) MedaSorb Technologies Corporation (OTCBB: MSBT) and its wholly-ownedsubsidiary, CytoSorbents, Inc., announced that it was approved toparticipate in the New Jersey Emerging Technology and BiotechnologyFinancial Assistance Program and sold its net operating loss, nettingapproximately $248,000 to the Company. This is in addition to the$840,000 raised in the second close of the Series B financing in August2008, bringing the total amount of capital raised by the Company to $5.5million over the past 7 months."This further bolsters our balance sheet to facilitate the completion ofour European Sepsis Trial evaluating the treatment of patients withsevere sepsis and respiratory failure with our CytoSorb(TM) resincartridge," commented Dr Phillip Chan, CEO. "Severe sepsis, often called'overwhelming infection,' is so prevalent that most people unfortunatelyknow someone who has died from this terrible disease.

CytoSorbents hopesto significantly impact the outcome of sepsis with its unique treatmentapproach."About MedaSorb, CytoSorbents and CytoSorb(TM)MedaSorb Technologies Corporation, with its wholly-owned operatingsubsidiary, CytoSorbents, Inc., is a medical device company focused on thetreatment of sepsis with its proprietary CytoSorb(TM) resin. Severe sepsisafflicts an estimated 18 million people worldwide each year, killing onein every three patients, despite the best medical treatment. CytoSorb(TM)is designed to treat sepsis by broadly reducing cytokines and toxins fromblood that can cause organ failure and potentially death. The Company is currently evaluating CytoSorb(TM)in its 60-80 patient, randomized, controlled, open-label European SepsisTrial.